National Institutes of Health: Stomach Neoplasms trials

The registry lists 62 Stomach Neoplasms studies with National Institutes of Health as lead sponsor. 8 are open to participants now and 23 have results posted.

Phase 1 22Phase 2 28Phase 3 1No phase 16(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The Vanguard Study: Testing a New Way to Screen for CancerRecruitingNCT06995898Not applicable
• Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaRecruitingNCT06885697Phase 1
• 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer DetectionRecruitingNCT06503146Phase 2
• Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid TumorsRecruitingNCT06364410Phase 1
• Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic AnalysisRecruitingNCT04557969
• Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 PatientsRecruitingNCT03190941Phase 1/2
• Tissue Procurement and Natural History Study of Patients With Malignant MesotheliomaRecruitingNCT01950572
• Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of CancerRecruitingNCT01915225
• Phase II Randomized Trial of Bethesda Protocol Compared to Cambridge Method for Detection of Early Stage Gastric Cancer in CDH1 Mutation CarriersCompletedNCT04535414Phase 2Results posted
• Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and IntestinesActive, not recruitingNCT04535401Phase 1Results posted
• Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal CarcinomatosisTerminatedNCT04034251Phase 2Results posted
• Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 PatientsTerminatedNCT03745326Phase 1/2Results posted
• Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer SyndromeCompletedNCT03648879Phase 2Results posted
• Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal CytologyCompletedNCT03092518Phase 2Results posted
• Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by SurgeryCompletedNCT03008278Phase 1/2Results posted
• Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal MetaplasiaActive, not recruitingNCT02782949Phase 2Results posted
• Predictors of Tumor Response and of Radiation Therapy Side Effects in Patients With Gastrointestinal CancersTerminatedNCT01445327Results posted
• Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction CancerCompletedNCT01260701Phase 2Results posted
• Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerCompletedNCT01010126Phase 2Results posted
• Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By SurgeryCompletedNCT00991952Phase 2Results posted
• Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction CancerCompletedNCT00982592Phase 2Results posted
• Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA TrialCompletedNCT00941655Phase 3Results posted
• Saracatinib in Treating Patients With Locally Advanced or Metastatic Stomach or Gastroesophageal Junction CancerCompletedNCT00607594Phase 2Results posted
• Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine CancerCompletedNCT00454363Phase 2Results posted
• Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction CancerCompletedNCT00253370Phase 2Results posted
• Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction CarcinomaCompletedNCT00084617Phase 2Results posted
• A Phase II Trial of STI571 in the Treatment of Metastatic Gastric CancerCompletedNCT00068380Phase 2Results posted
• A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction CancerTerminatedNCT00064259Phase 1/2Results posted
• Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal JunctionCompletedNCT00062374Phase 2Results posted
• Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or StomachCompletedNCT00061932Phase 2Results posted
• Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach CancerCompletedNCT00006389Phase 2Results posted
• Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialActive, not recruitingNCT04704661Phase 1
• Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair VariationsActive, not recruitingNCT04550494Phase 2
• National Cancer Institute "Cancer Moonshot Biobank"Active, not recruitingNCT04314401
• Gastric Cancer Precursor Lesions (GCPL) StudyCompletedNCT03188406
• Discovery and Validation of Plasma DNA Methylation Biomarker for Detection of Stomach CancerCompletedNCT03076567
• Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric CancerCompletedNCT03030404
• Prospective Evaluation and Molecular Profiling in People With Gastric TumorsCompletedNCT03027427
• Helicobacter Pylori Genome Project (HpGP)TerminatedNCT02788214
• Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney DysfunctionWithdrawnNCT02567396Phase 1
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation TherapyActive, not recruitingNCT02381561Phase 1
• Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By SurgeryTerminatedNCT01705340Phase 1
• TKM 080301 for Primary or Secondary Liver CancerCompletedNCT01437007Phase 1
• Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid TumorsTerminatedNCT01233505Phase 1
• Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine CarcinomaCompletedNCT01204476Phase 1
• The Natural History of Solid Organ Cancer Stem Cells (SOCSC)TerminatedNCT00923052
• Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerCompletedNCT00397384Phase 1
• Nutrition Intervention Trials in Linxian Follow-up StudyCompletedNCT00342654
• A Prospective Cohort Study of Occupational Exposures and Cancer Risk Among WomenCompletedNCT00342004
• Early Detection of Esophageal CancerTerminatedNCT00341523
• S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach CancerCompletedNCT00103324Phase 2
• Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid TumorsCompletedNCT00089362Phase 1
• EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung CancerTerminatedNCT00087191Not applicable
• Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaCompletedNCT00084604Phase 2
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
• Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic CancerCompletedNCT00028496Phase 1
• Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid TumorCompletedNCT00021047Phase 1/2
• LMB-9 Immunotoxin in Treating Patients With Advanced Solid TumorsCompletedNCT00019435Phase 1
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
• A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by RituximabCompletedNCT00001805Phase 2
• Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal CarcinomatosisCompletedNCT00001332Phase 1